| Literature DB >> 26512307 |
Markus Reinholz1, Markus Heppt1, Julia K Tietze1, Thomas Ruzicka1, Gerd G Gauglitz1, Jürgen Schauber1.
Abstract
Cutaneous scars develop as a result of a defective wound healing process. Scars are commonly visible as erythematous, sometimes disfiguring lesions which might be stigmatizing for the affected patient. Only a few therapies to improve the appearance of scars are available. Recently, brimonidine - a selective α2-receptor-agonist which causes vasoconstriction of small cutaneous vessels - was approved for the treatment of erythemato-telangiectatic rosacea. Topical brimonidine might also be helpful to improve redness of immature scars. Here we report on the effect of brimonidine 0.5% gel on a flat, erythematous scar in a 25-year-old female patient. Whitening of the scar could be observed immediately after application of brimonidine 0.5% gel and a good clinical result was observed within one hour. This effect lasted for up to three hours. We conclude that brimonidine 0.5% gel is a suitable topical therapy to reduce erythema in visible cutaneous scars.Entities:
Keywords: brimonidine gel; erythema; immature scar; scar; topical therapy
Year: 2015 PMID: 26512307 PMCID: PMC4619167 DOI: 10.3315/jdcr.2015.1210
Source DB: PubMed Journal: J Dermatol Case Rep ISSN: 1898-7249